Search results for " Humans"

showing 10 items of 2466 documents

Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation.

2007

Object The objectives of this study were to examine whether the systemic administration of recombinant human erythropoietin (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery in a rat model of sciatic nerve injury, and to compare the effects of these agents in the model. Methods Thirty male Sprague–Dawley rats received a crush injury to the left sciatic nerve and subsequently underwent either placebo treatment, daily injections of rHuEPO, or weekly injections of darbepoetin alfa. Results Both rHuEPO and darbepoetin alfa were effective in reducing neurological impairment and improving compound muscle action potentials following nerve injury. Darbepoetin …

MaleTime FactorsDarbepoetin alfaNerve CrushAction PotentialsPlaceboDrug Administration ScheduleRats Sprague-Dawleyadministration /&/ dosage/pharmacologymedicineAnimalsHumansDarbepoetin alfaMuscle SkeletalErythropoietinERYTHROPOIETINdrug effects/injuries/physiopathologySettore MED/27 - Neurochirurgiabusiness.industryAction Potentials; drug effects Animals Drug Administration Schedule Erythropoietin; administration /&/ dosage/analogs /&/ derivatives/pharmacology Humans Male Muscle; Skeletal; physiopathology Nerve Crush Neuroprotective Agents; administration /&/ dosage/pharmacology Rats Rats; Sprague-Dawley Recombinant Proteins Recovery of Function; drug effects Sciatic Nerve; drug effects/injuries/physiopathology Time FactorsGeneral MedicineSkeletalRecovery of FunctionNerve injurySciatic nerve injurymedicine.diseaseadministration /&/ dosage/analogs /&/ derivatives/pharmacologySciatic NerveNeuroprotectionRecombinant ProteinsRatsNeuroprotective AgentsNeurologyErythropoietinPeripheral nerve injuryAnesthesiadrug effectsPeripheral nerve injuryCrush injuryMuscleSurgeryNeurology (clinical)Sciatic nerveSprague-Dawleymedicine.symptomphysiopathologybusinessmedicine.drug
researchProduct

Prevalence of fatigue in Parkinson disease and its clinical correlates

2014

Objective: To assess in a noninterventional setting the prevalence and severity of fatigue in patients with Parkinson disease (PD). Methods: This was a cross-sectional study conducted in Italian patients with PD. Objectives included the evaluation of the current prevalence and severity of fatigue in patients with PD measured using the 16-item Parkinson Fatigue Scale (PFS-16), distressing fatigue (defined as a PFS-16 mean score $3.3), and assessment of its clinical correlates. Results: A total of 402 patients were enrolled and 394 patients completed the PFS-16 questionnaire with a PFS-16 mean (6SD) score of 2.87 6 0.99. Of these, 136 patients (33.8%) reported distressing fatigue (PFS-16 mean…

MaleTime FactorsDiseaseDSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD-10 5 International Classification of Diseases 10th revision; MAO-B 5 monoamine oxidase B; MS 5 multiple sclerosis; PD 5 Parkinson disease; PDQ-39 5 39-item Parkinson’s Disease Questionnaire; PDSS 5 Parkinson’s Disease Sleep Scale; PFS-16 5 16-item Parkinson Fatigue Scale; UPDRS 5 Unified Parkinson’s Disease Rating ScaleSeverity of Illness IndexQuality of life80 and overPrevalencePDSS 5 Parkinson’s Disease Sleep ScaleAge FactorDepression (differential diagnoses)FatigueAged 80 and overDepressionmusculoskeletal neural and ocular physiologyAge FactorsParkinson DiseasePDQ-39 5 39-item Parkinson’s Disease QuestionnaireMiddle AgedItalyPFS-16 5 16-item Parkinson Fatigue ScaleFemaleSettore MED/26 - NeurologiaMS 5 multiple sclerosiPsychologyHumanAdultSleep Wake Disordersmedicine.medical_specialtyPD 5 Parkinson diseasemacromolecular substancesArts and Humanities (miscellaneous)Internal medicinemedicineDistressingHumansIn patientAgedCross-Sectional StudieMAO-B 5 monoamine oxidase BUPDRS 5 Unified Parkinson’s Disease Rating Scalenervous system diseasesAdult; Age Factors; Aged; Aged 80 and over; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Neurology (clinical); Arts and Humanities (miscellaneous)Cross-Sectional Studiesnervous systemICD-10 5 International Classification of Diseases 10th revisionPhysical therapyNeurology (clinical)DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th editionSleep Disorder
researchProduct

Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

2021

Background and aims: Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. Methods and results: In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We…

MaleTime FactorsEndocrinology Diabetes and MetabolismCardiovascular risk Direct acting antiviralsHepatitis C virusPrediabetes Aged Antiviral Agents Cardiovascular Diseases FemaleHeart Disease Risk Factors Hepatitis C Humans Incidence Italy Longitudinal Studies Male Middle Aged Prediabetic State Prospective Studies Protective Factors Retrospective Studies Risk AssessmentTime Factors Treatment Outcome Viral LoadMedicine (miscellaneous)Type 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeDIRECT ACTING ANTIVIRALSLiver disease0302 clinical medicineLongitudinal StudiesProspective StudiesPrediabeteseducation.field_of_studyNutrition and DieteticsIncidenceMiddle AgedViral LoadHepatitis CTreatment OutcomeItalyCardiovascular DiseasesCohortFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyHepatitis C virusPopulation030209 endocrinology & metabolismAntiviral AgentsRisk AssessmentPrediabetic State03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective Studiesbusiness.industryProtective FactorsCardiovascular riskmedicine.diseaseHeart Disease Risk FactorsDirect acting antiviralHepatitis C virubusinessPrediabetesMace
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct

Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes - The TOSCA.IT study

2016

Background and aims: Diabetic women have a more adverse plasma lipid profile than men. Sex differences in dietary habits may play a role, but are little investigated. The study evaluates the quality of diet, adherence to the nutritional recommendations of the Diabetes and Nutrition Study Group and their relation with plasma lipid in men and women with diabetes. Methods and results: We studied 2573 people, aged 50e75, enrolled in the TOSCA.IT study (clinicaltrials.gov; NCT00700856). Plasma lipids were measured centrally. Diet was assessed with a semi-quantitative food frequency questionnaire.Women had a more adverse plasma lipid profile than men.Women consumed significantly more legumes, veg…

MaleTime FactorsHealthy DietEndocrinology Diabetes and MetabolismSaturated fatMedicine (miscellaneous)Type 2 diabetesCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Medicine (miscellaneous); Nutrition and Dietetics; Endocrinology Diabetes and Metabolism; Cardiology and Cardiovascular MedicineDiabeteRecommended Dietary AllowancesChoice Behaviorchemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Feeding Behavior; Healthy Diet; Patient Compliance; Recommended Dietary Allowances; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSurveys and QuestionnairesFood choiceMedicine030212 general & internal medicineFood scienceCardiovascular risk factorsNutrition and DieteticsDietary habitsDiabetesMenMiddle AgedLipidsDiabetes and MetabolismTreatment OutcomeItalySaturated fatty acidFemaleDiet HealthyCardiology and Cardiovascular MedicineType 2030209 endocrinology & metabolismAdded sugarDietary habit03 medical and health sciencesFood PreferencesSex FactorsDiabetes mellitusSex differencesDiabetes MellitusHumansWomenAgedCardiovascular risk factors; Diabetes; Dietary habits; Men; Nutritional recommendations; Sex differences; Women; Aged; Biomarkers; Diabetes Mellitus Type 2; Female; Food Preferences; Humans; Italy; Lipids; Male; Middle Aged; Nutrition Assessment; Risk Factors; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Choice Behavior; Diet Healthy; Feeding Behavior; Patient Compliance; Recommended Dietary AllowancesHealthybusiness.industryUnsaturated fatNutritional recommendationFeeding BehaviorSex differencemedicine.diseaseDietNutrition AssessmentchemistryDiabetes Mellitus Type 2Patient ComplianceNutritional recommendationsGlycated hemoglobinbusinessBiomarkers
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III

2006

International audience; Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels--for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C-->A and c.1032C-->G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor…

MaleTime FactorsKinins030204 cardiovascular system & hematologyMESH: Founder Effect[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityLinkage Disequilibrium0302 clinical medicineMissense mutationHereditary Angioedema Type IIIGenetics(clinical)MESH: Models GeneticGenetics (clinical)MESH: Heterozygote0303 health sciencesFactor XII[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyFounder EffectMarkov ChainsPedigree3. Good healthMESH: Linkage DisequilibriumFactor XIIHereditary angioedemaFemalemedicine.symptomMESH: Factor XIIHeterozygotemedicine.medical_specialtyMESH: MutationMESH: PedigreeMESH: Bayes TheoremCoagulation Factor XIIBiology03 medical and health sciencesMESH: Markov ChainsReportInternal medicinemedicineGeneticsHumansMESH: AngioedemaAngioedema030304 developmental biologyMESH: HumansModels GeneticAngioedemaHaplotypeMESH: Time FactorsBayes TheoremHeterozygote advantageMESH: Haplotypesmedicine.diseaseMESH: KininsMESH: MaleEndocrinologyHaplotypesMutationImmunologyMESH: Microsatellite RepeatsMESH: FemaleMicrosatellite RepeatsThe American Journal of Human Genetics
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct